GBT vs. ALKS, PRGO, ELAN, MDGL, GRFS, IONS, RXDX, CERE, ITCI, and PTCT
Should you be buying Global Blood Therapeutics stock or one of its competitors? The main competitors of Global Blood Therapeutics include Alkermes (ALKS), Perrigo (PRGO), Elanco Animal Health (ELAN), Madrigal Pharmaceuticals (MDGL), Grifols (GRFS), Ionis Pharmaceuticals (IONS), Prometheus Biosciences (RXDX), Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), and PTC Therapeutics (PTCT). These companies are all part of the "medical" sector.
Global Blood Therapeutics vs.
Global Blood Therapeutics (NASDAQ:GBT) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends.
In the previous week, Alkermes had 6 more articles in the media than Global Blood Therapeutics. MarketBeat recorded 6 mentions for Alkermes and 0 mentions for Global Blood Therapeutics. Global Blood Therapeutics' average media sentiment score of 0.52 beat Alkermes' score of 0.19 indicating that Global Blood Therapeutics is being referred to more favorably in the media.
Global Blood Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
Global Blood Therapeutics presently has a consensus target price of $67.75, suggesting a potential downside of 1.08%. Alkermes has a consensus target price of $30.63, suggesting a potential upside of 8.64%. Given Alkermes' stronger consensus rating and higher probable upside, analysts plainly believe Alkermes is more favorable than Global Blood Therapeutics.
Alkermes has higher revenue and earnings than Global Blood Therapeutics. Alkermes is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.
Alkermes received 98 more outperform votes than Global Blood Therapeutics when rated by MarketBeat users. However, 71.23% of users gave Global Blood Therapeutics an outperform vote while only 71.04% of users gave Alkermes an outperform vote.
Alkermes has a net margin of -14.23% compared to Global Blood Therapeutics' net margin of -137.30%. Alkermes' return on equity of -3.32% beat Global Blood Therapeutics' return on equity.
96.2% of Alkermes shares are held by institutional investors. 4.9% of Global Blood Therapeutics shares are held by company insiders. Comparatively, 4.8% of Alkermes shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Alkermes beats Global Blood Therapeutics on 13 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Global Blood Therapeutics Competitors List
